

Why carry out this study?

- Many disease-modifying therapies for multiple sclerosis (MS) require regular self-injection.
- These injections can be associated with injection-site reactions, pain, and needle/injection phobia - but improvements in autoinjector design may address these problems.
- The aim of this study was to investigate patient satisfaction and preference for BETACONNECT™ (Bayer HealthCare Pharmaceutical, Inc.), a novel interferon beta-1b autoinjector.

What was learned from this study?

- BETACONNECT was preferred by 90% of patients with MS over their previous injection method, mostly because of ease of use, less irritation/pain at the injection site, and smoother injections.
- Patients with MS self-injecting interferon beta-1b expressed a high level of satisfaction and preference for BETACONNECT, which thus represents a valid option to improve patients' overall injection experience.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Bayer HealthCare Pharmaceuticals, Inc. Medical writing assistance for this study was provided by Dr Richard Clark (freelance medical writer, Dunchurch, Warwickshire, UK). For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).